CarThera

CarThera is pioneering a novel approach to treating severe brain diseases by using its proprietary SonoCloud® implantable ultrasound device to temporarily and reversibly open the blood-brain barrier, thereby increasing drug concentration in the brain. The company's lead program is in a pivotal trial (SONOBIRD) for recurrent glioblastoma, with a pipeline exploring applications in brain metastases and neurodegenerative diseases. Backed by four venture capital funds and led by a team of specialists, CarThera is advancing its technology through key clinical trials and strategic partnerships with international pharmaceutical companies.

SonoCloud® implantable low-intensity pulsed ultrasound (LIPU) device designed to temporarily and reversibly open the blood-brain barrier (BBB) to enhance delivery of therapeutic agents.

CarThera competes in the space of BBB disruption technologies, which includes other focused ultrasound companies (e.g., Insightec, in partnership with biopharma) and alternative delivery methods like convection-enhanced delivery or nanoparticle carriers. CarThera's implantable, repeat-use device differentiates it from some non-invasive transcranial focused ultrasound approaches.